Definium Therapeutics (DFTX) Income from Continuing Operations (2021 - 2026)
Definium Therapeutics' (DFTX) quarterly Income from Continuing Operations came in at 58205928000.0 in Q1 2026, down 191821.42% year-on-year from N/an in Q1 2025, and down 128183.18% on a QoQ basis from 45373000.0 in Q4 2025.
Definium Therapeutics (DFTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Income from Continuing Operations data on file, last reported at 58205928000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 191821.42% year-over-year to 58205928000.0 in Q1 2026; TTM through Mar 2026 was 60862013000.0, a 58428.48% decrease from a year earlier, with the FY2025 full-year figure at 31062295000.0, down 632.56% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 58205928000.0, down from 45373000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for DFTX reached as high as 5127000.0 in Q4 2022 and fell as low as 58205928000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 3596639007.24 across 5 years, with a median of 22012000.0 in 2024.
- Across the five-year window, Income from Continuing Operations soared 62.53% in 2022 and plunged 191821.42% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 5127000.0 in 2022, then slumped by 305.93% to 20812000.0 in 2023, then plunged by 43.37% to 29839000.0 in 2024, then plunged by 52.06% to 45373000.0 in 2025, then tumbled by 128183.18% to 58205928000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 58205928000.0 in Q1 2026, 45373000.0 in Q4 2025, and 44707000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Definium Therapeutics | 4.71 Bn | 4.71 Bn | - | -58.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.21 Bn |
| Dec 31, 2025 | -45.37 Mn |
| Sep 30, 2025 | -44.71 Mn |
| Jun 30, 2025 | -2.57 Bn |
| Mar 31, 2025 | -30.33 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -20.98 Mn |
| Dec 31, 2023 | -20.81 Mn |
| Sep 30, 2023 | -21.06 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | -5.13 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -27.99 Mn |
| Dec 31, 2021 | 46.37 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |